Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum

Deciphera 药业出席 JMP 证券血液学和肿瘤论坛

2020-06-11 22:00:25 BioSpace

本文共850个字,阅读需3分钟

WALTHAM, Mass.---- Deciphera Pharmaceuticals, Inc. today announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:40 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation. About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK™ is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor. For more information, please visit the Company’s website at www.deciphera.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005176/en/ Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc jrobinson@deciphera.com 781-906-1112 Media: David Rosen Argot Partners David.Rosen@argotpartners.com 212-600-1902 Source: Deciphera Pharmaceuticals, Inc. View this news release online at: http://www.businesswire.com/news/home/20200611005176/en
马萨诸塞州沃尔瑟姆.-----Deciphera Pharmaceuticals , Inc .今天宣布,首席财务官兼财务官兼财务长 Tucker Kelly 将于2020年6月18日(星期四)下午2:40在 JMP 证券血液学和肿瘤学论坛上发表讲话。会议将以虚拟会议形式举行。 本次活动的现场网络直播将在本公司网站“投资者”部分的“活动与演示”页面上,网址为 https://investors 。破译。com / news-events / events-presentation 。在演示后90天内,将在公司网站上重新播放该网络广播。 关于 Deciphera 制药公司 Deciphera 是一家致力于发现、开发和商业化重要新药以改善癌症患者生活的生物制药公司。我们正在利用我们专有的开关控制激酶抑制剂平台和激酶生物学方面的深厚专业知识,开发广泛的创新药物组合。除了在临床研究中从我们的平台上推进多个产品候选项目外, QNLOCK ™是 Deciphera 批准的用于治疗第四线胃肠道间质瘤的开关控制激酶抑制剂。有关详细信息,请访问公司网站 www.decphera.com 。 查看 businesswire 上的源代码。com : https://www.businesswire.com/news/home/2020061005176/en/ 投资者关系: Jen Robinson Deciphera Pharmaceuticals , Inc jrobinson @ decphera.com 781-906-1112 媒体: David Rosen Argot Partners 大卫。Rosen @ argotpartners.com 212-600-1902 资料来源: Deciphera Pharmaceuticals , Inc 。 在线查看本新闻稿,网址为: http://www.businesswire.com/news/home/2020061005176/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文